UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 141

Sortiert nach

A retrospective analysis to identify predictors of COPD-related rehospitalization

BMC pulmonary medicine, 2016-04, Vol.16 (1), p.68-68, Article 68

2016

Volltextzugriff (PDF)

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

BMC psychiatry, 2011-10, Vol.11 (1), p.168-168, Article 168

2011

Volltextzugriff (PDF)

Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence

Archives of physical medicine and rehabilitation, 2007-05, Vol.88 (5), p.646-652

2007

Volltextzugriff (PDF)

Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants

Clinical therapeutics, 2019-02, Vol.41 (2), p.269-279

2019

Volltextzugriff (PDF)

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

Current medical research and opinion, 2011-08, Vol.27 (8), p.1603-1611

2011

Volltextzugriff (PDF)

Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence

European urology, 2007-09, Vol.52 (3), p.850-859

2007

Volltextzugriff (PDF)

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

BMC psychiatry, 2011-10, Vol.11 (1), p.167-167, Article 167

2011

Volltextzugriff (PDF)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

Annals of general psychiatry, 2011-04, Vol.10 (1), p.10-10, Article 10

2011

Volltextzugriff (PDF)

Cost and utilization of healthcare services for hip and knee replacement

Journal of medical economics, 2013-07, Vol.16 (7), p.888-896

2013

Volltextzugriff (PDF)

Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Exploratory Study with Epoetin Alfa

Journal of the American Geriatrics Society (JAGS), 2007-10, Vol.55 (10), p.1557-1565

2007

Volltextzugriff (PDF)

Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis

Journal of managed care & specialty pharmacy, 2014-08, Vol.20 (8), p.800-807

2014

Volltextzugriff (PDF)

Primary focal hyperhidrosis: disease characteristics and functional impairment

Dermatology (Basel), 2006-01, Vol.212 (4), p.343

2006

Volltextzugriff (PDF)

Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension

Annals of general psychiatry, 2010-06, Vol.9 (1), p.24-24, Article 24

2010

Volltextzugriff (PDF)

Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine

Drug safety, 2007, Vol.30 (7), p.589-599

2007

Volltextzugriff (PDF)

A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs

Multiple sclerosis journal - experimental, translational and clinical, 2018-10, Vol.4 (4), p.2055217318819031

2018

Volltextzugriff (PDF)

Complexity of pain management among patients with nociceptive or neuropathic neck, back, or osteoarthritis diagnoses

Journal of managed care & specialty pharmacy, 2014-05, Vol.20 (5), p.455-466

2014

Volltextzugriff (PDF)

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study

BMC pulmonary medicine, 2011-12, Vol.11 (1), p.61-61, Article 61

2011

Volltextzugriff (PDF)

Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders

Journal of medical economics, 2015-01, Vol.18 (8), p.646-653

2015

Volltextzugriff (PDF)

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

Journal of medical economics, 2014-06, Vol.17 (6), p.384-393

2014

Volltextzugriff (PDF)

Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence

Journal of medical economics, 2014-12, Vol.17 (12), p.872-880

2014

Volltextzugriff (PDF)

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

Journal of medical economics, 2015-01, Vol.18 (8), p.637-645

2015

Volltextzugriff (PDF)

Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy

Current medical research and opinion, 2012-09, Vol.28 (9), p.1485-1496

2012

Volltextzugriff (PDF)

Medicaid Eligibility and Time to Re-incarceration Among Previously Incarcerated Subjects With Schizophrenia

Journal of health economics and outcomes research (Online), 2016-10, Vol.3 (1), p.97-107

2016

Volltextzugriff (PDF)

S0762 Nonbiologic Drug Use One Year Before and Two Years After Initiation of Ustekinumab or Adalimumab for Crohn's Disease Patients

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S386-S389

2020

Volltextzugriff (PDF)

Mo1876 TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR USTEKINUMAB AND ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE WITH TWO-YEARS FOLLOW-UP IN THE SYMPHONY HEALTH DATABASE

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-959-S-959

2020

Volltextzugriff (PDF)

1 – 25 von 141

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(138)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(141)

Sprache

Englisch
(141)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A retrospective analysis to identify predictors of COPD-related rehospitalization

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence

Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

Botulinum Toxin A Improves the Quality of Life of Patients with Neurogenic Urinary Incontinence

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

Cost and utilization of healthcare services for hip and knee replacement

Chronic Anemia and Fatigue in Elderly Patients: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Exploratory Study with Epoetin Alfa

Use of an early disease-modifying drug adherence measure to predict future adherence in patients with multiple sclerosis

Primary focal hyperhidrosis: disease characteristics and functional impairment

Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension

Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine

A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs

Complexity of pain management among patients with nociceptive or neuropathic neck, back, or osteoarthritis diagnoses

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study

Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence

Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement

Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy

Medicaid Eligibility and Time to Re-incarceration Among Previously Incarcerated Subjects With Schizophrenia

S0762 Nonbiologic Drug Use One Year Before and Two Years After Initiation of Ustekinumab or Adalimumab for Crohn's Disease Patients

Mo1876 TREATMENT PERSISTENCE AND MAINTENANCE DOSING FOR USTEKINUMAB AND ADALIMUMAB AMONG PATIENTS WITH CROHN'S DISEASE WITH TWO-YEARS FOLLOW-UP IN THE SYMPHONY HEALTH DATABASE

Suchergebnisse filtern